Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

NCT05308264 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Risk Myelodysplastic Syndromes

Interventions

DRUG: R906289 Monosodium (R289 Na)

Sponsor

Rigel Pharmaceuticals